NASDAQ:CVAC CureVac Q1 2025 Earnings Results & Report $4.66 0.00 (0.00%) As of 10/7/2026 CureVac missed analyst expectations on both earnings and revenue in its Q1 2025 results, released May 22, 2025. The company reported EPS of -$0.24 versus the -$0.16 consensus estimate, while revenue of $0.94 million fell short of the $4.27 million estimate by $3.33 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 22, 2025TimeBefore Market OpensConference Call DateMay 20, 2025Conference Call2:00 AM ET CureVac EPS ResultsActual EPS-$0.24Consensus EPS -$0.16Beat/MissMissed by -$0.08One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCureVac Revenue ResultsActual Revenue$0.94 millionExpected Revenue$4.27 millionBeat/MissMissed by -$3.33 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) CureVac Q1 2025 Earnings FAQ Did CureVac beat earnings estimates for Q1 2025? CureVac (NASDAQ:CVAC) reported earnings of -$0.24 per share for Q1 2025, missing the consensus estimate of -$0.16. The report was announced on Thursday, May 22, 2025. What was CureVac's revenue for Q1 2025? CureVac reported revenue of $0.94 million for Q1 2025, against a consensus estimate of $4.27 million. CureVac Earnings HeadlinesReviewing CollPlant Biotechnologies (NASDAQ:CLGN) & CureVac (NASDAQ:CVAC)October 6 at 12:15 PM | americanbankingnews.comReviewing CureVac (NASDAQ:CVAC) & Longeveron (NASDAQ:LGVN)October 2, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)CureVac sues Moderna for patent infringement over COVID-19 vaccinesApril 24, 2026 | reuters.comCureVac (NasdaqGM:CVAC) Valuation After New mRNA Pipeline Progress And Refined Capital Allocation PlanJanuary 22, 2026 | finance.yahoo.comBioNTech Completes CureVac Takeover and Updates Articles of AssociationJanuary 6, 2026 | tipranks.comSee More CureVac Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email. Email Address About CureVacCureVac (NASDAQ:CVAC) (NASDAQ: CVAC) is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA). Its research programs are aimed at using mRNA to instruct cells to produce therapeutic proteins, with applications in infectious diseases, oncology and other medical conditions. Founded in 2000 and headquartered in Tübingen, Germany, CureVac has developed proprietary mRNA technologies designed to improve the stability, delivery and manufacturing of mRNA-based products. The company has advanced experimental vaccine and therapeutic candidates through preclinical and clinical development, but it does not have a broad portfolio of approved commercial products. CureVac’s programs have included candidates for COVID-19 and seasonal influenza, as well as cancer immunotherapies and other vaccines. The company has conducted research and clinical activities across Europe and the United States and has pursued development and commercialization collaborations, including a strategic partnership with GSK. Alexander Zehnder served as CureVac’s chief executive officer beginning in 2023.View CureVac ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
